Depleting NFAT1 expression inhibits the ability of invasion and migration of human lung cancer cells.

Background: Nuclear factor of activated T-cells (NFAT) is a general name applied to a family of transcription factors shown to be important in immune response. One or more members of the NFAT family are expressed in most cells of the immune system. NFAT1 is considered to involve in the development of cardiac, skeletal muscle, nervous systems, and tumorigenesis.

Synchronous primary carcinosarcoma and adenosquamous carcinoma of the esophagus.

Reports of adenosquamous carcinoma and carcinosarcoma found at the same esophagus are rare in the literature. We report a case of synchronous adenocarcinoma and carcinosarcoma of the esophagus. The sarcomatous components were immunoreactive for vimentin.

Expression and unique functions of four nuclear factor of activated T cells isoforms in non-small cell lung cancer.

Nuclear factor of activated T cells (NFAT) is an important family of transcription factors that can be activated by calmodulin and calcineurin in human cells. To investigate the expression and clinical significance of NFAT isoforms and calcineurin in non-small cell lung cancer (NSCLC), we collected tumor and adjacent normal tissues from 159 NSCLC patients and assembled them in a tissue microarray. Protein levels of NFAT1, NFAT2, NFAT3, NFAT4, and calcineurin were determined using immunohistochemistry.

A retrospective study of unicentric and multicentric Castleman's disease: a report of 52 patients.

Castleman's disease (CD) is a rare disorder characterized by non-cancerous tumor growth that may develop in the lymph node tissue at a single site or throughout the body (Castleman et al. in Cancer 9:822-830, 1956). It involves hyperproliferation of specific B cells that produce the cytokine IL-6.

Multiple organ metastases of Pulmonary Epithelioid Haemangioendothelioma and a review of the literature.

This report describes a case of pulmonary epithelioid haemangioendothelioma presented as multi-organ metastases including lung, liver and bone in a 56-year-old woman with an initial diagnosis made with thoracoscopic wedge biopsy. The diagnosis is confirmed through immunohistochemistry. This is a rare disease, with approximately 90 cases described in the English literature and approximately 10 cases reported in China.

[The role of surgical resection in treating small cell lung cancer].

Compares with non-small cell lung cancer, small cell lung cancer (SCLC) generally has a more rapid doubling time, a higher growth fraction, and earlier development of widespread metastases. Surgical operation has little impact on long-term survival of SCLC patients. Chemotherapy with combined radiotherapy has been recommended as the main treatment of SCLC.